Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 422 (OTC: $CSUI)
(NASDAQ: $HUGE) (TSX: $RIV.TO) (OTCQB: $CBDY) (TSX: $HEXO.TO) (OTC: $CURR)
Delta, Kelowna, BC, June 3, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/06031CSUI-HUGE-RIV-CBDY-HEXO-CURR.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s
podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI), a research & development company licensed under
Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The
Company's facilities for producing cannabis are based in Zurich.
The
Company grows high quality, organic cannabis with sustainable, all-natural
principles. Cannabis Suisse products are laboratory tested to ensure the end
users have access to a standardized, safe and consistent product.
In
today’s podcast we will be looking at a few public company announcements.
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) had a “huge” run today, up nearly
180%, after having announced that the U.S. Food and Drug
Administration (FDA) has given the company permission to submit an Investigational
New Drug Application (IND) for the use of FSD-201 (ultramicronized
palmitoylethanolamide, or ultramicronized PEA)
to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe
COVID-19 is characterized by an over-exuberant inflammatory response that may
lead to a cytokine storm and ultimately death. FSD Pharma is focused on
developing FSD-201 for its anti-inflammatory properties to avoid the cytokine
storm associated with acute lung injury in hospitalized COVID-19 patients.
"FDA's
permission to design a proof-of-concept study in COVID-19 patients evaluating
clinical doses of FSD-201 is a paradigm shift for FSD Pharma and is the result
of outstanding work conducted by Dr. Edward Brennan, President FSD BioSciences,
and his team," said Raza Bokhari, MD, Executive Co-Chairman & CEO.
"We contacted the FDA in late-March 2020 after becoming aware that several
Italian physicians and scientists were advocating for use of ultramicronized
PEA for patients suffering from symptoms of COVID-19, based on the drug's
mechanism of action as a potent and safe anti-inflammatory agent that reduces
the production of pro-inflammatory cytokines. Numerous studies over the past 40
years also validate the efficacy and safety of ultramicronized PEA in the
treatment and prophylactic effects in respiratory infections. These studies
also pointed out that the ease of application of PEA offers the possibility to
have a quick therapeutic answer ready in case of a flu epidemic."
Based
on the FDA feedback received to date, we expect the trial will be a randomized,
controlled, double-blind, U.S. multicenter study to assess the efficacy and
safety of FSD-201 dosed 600mg or 1200mg twice-daily plus standard of care (SOC)
versus SOC alone in symptomatic patients with clinical presentation compatible
with COVID-19. Eligible patients will present with symptoms consistent with
influenza/coronavirus signs (fever, dry cough, malaise, difficulty breathing)
and/or newly documented positive COVID-19 disease.
The
primary endpoint is to determine if FSD-201 plus SOC provides a significant
improvement in clinical status (i.e., shorter time to symptom relief). Key
secondary objectives include determining if FSD-201 plus SOC demonstrates
additional benefit in terms of safety, objective assessments such as length of
time to normalization of fever, length of time to improvement of oxygen
saturation and length of time to clinical progression including time to
mechanical ventilation or hospitalization, and length of hospital stay. The
exploratory endpoint is cytokine clearance as measured by Enzyme Linked
Immunosorbent Assay (ELISA).
The
treatment period is expected to be 14 days.
All patients who experience clinical benefit are expected to continue to
receive their assigned treatment until study completion.
Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF), a venture capital firm
specializing in cannabis, today released its audited consolidated
financial statements for the fiscal year ended March 31, 2020 and management's
discussion and analysis for the three and twelve months ended March 31, 2020.
"The
global economic uncertainty brought on by COVID-19 capped off a volatile and
challenging year for the cannabis sector. Despite these challenges, I am pleased
with what our team achieved last year. However, we were not immune to this
volatility, and following a strategic and operational review of our business,
we recently announced a number of changes aimed at strengthening our financial
discipline and positioning Canopy Rivers for sustained success moving
forward," said Narbé Alexandrian, President and CEO of Canopy Rivers.
"Reflecting on the past year, there were several significant achievements
that make me optimistic for fiscal year 2021. First, our portfolio companies
reached new milestones, including the licensing of PharmHouse, the expansion of
TerrAscend's U.S. operations, and ZeaKal's successful trials of its PhotoSeed™
technology. Second, our graduation to the TSX and the launch of our Strategic
Advisory Board signalled our company's continued maturation. Finally, we made
four new investments, including two in ag-tech, which we believe is a critical
component of the value chain that is poised to disrupt the cannabis
sector."
"While
headwinds persist, we remain positive as we evaluate new opportunities that we
believe will ultimately create value for our shareholders and help build the
cannabis industry of tomorrow," added Alexandrian.
"Looking
back on FY 2020, it is clear that cannabis companies encountered challenging
conditions in the capital markets over those 12 months, and the impact of this
shows in our financial results for the fiscal year," said Eddie Lucarelli,
CFO of Canopy Rivers. "However, we believe that this is more of a function
of the slower-than-expected pace of development of the cannabis economy, rather
than its long-term potential, which we continue to believe is significant.
Based on our available cash resources and deep sector insights, we believe we
are well-positioned to capitalize on the current market conditions and
strengthen our portfolio of cannabis disruptors."
TARGET GROUP INC. (OTCQB: CBDY) announced that its wholly owned subsidiary,
Canary RX Inc. has entered into an agreement to form a Joint Venture
Partnership with THRIVE CANNABIS INC. in Norfolk County, ON for the production
of premium craft cannabis.
The
terms of the 5 year definitive agreement have Target and Thrive each with a 50%
ownership of the JV. Target, via its wholly owned subsidiary Canary RX Inc.
will permit Thrive to produce premium craft grown cannabis in 7 of its 8, 2300
square foot growing rooms within its existing 44,000 sq. ft. licenced
cultivation facility in Norfolk County, ON. In addition, Thrive will maintain
and supervise the staff on their proprietary methods of cultivation that it
currently utilizes from its production in Canada. Operations within the
facility are expected to begin immediately.
This
partnership is anticipated to increase the initial production yields within the
Canary RX facility and will encompass stronger cultivation management led by an
already proven team. Once operational, the JV will begin producing premium
craft cannabis for both Target and Thrive, to supply existing distribution
networks in Canada. The JV will, additionally, utilize formulations from both
parties in Canada as well as manufacture proprietary branded products that both
parties plan to distribute throughout their respective supply chains.
"Moving
forward with Thrive Cannabis in the form of this JV allows us to execute our
growth strategy more quickly and efficiently. Their knowledge in maximising the
growth of cannabis in our Canary Rx facility and development of genetics is
next to none. We are very excited with the Thrive partnership and experience
their team brings" said Tony Zarcone, Target Group's CEO.
"This
is a world class asset to take on under our management that adds substantial
capacity for the cultivation of premium indoor flower. We could not be happier
to be partnering with Canary RX for the mutual benefit of our organizations and
shareholders," said Geoff Hoover, Thrive CEO.
The
JV will also look to manufacture white label products for other licensed
producers throughout Canada, and it is currently in talks with several
potential customers to produce other value-added cannabis products such as
tinctures, topicals, pre-rolls, food products and formulated bulk THC/CBD oil.
HEXO Corp (TSX: HEXO) (NYSE: HEXO) announced the launch of a new 30 gram medical
flower format for its popular high-THC strain Tsunami under HEXO medical
cannabis.
HEXO has been
dedicated to providing Canadian clients high quality medical cannabis since
2015. A year ago, the Company updated its medical packaging to comply with the
Cannabis Regulations, resulting in smaller product formats. HEXO is proud to launch a new 30 g format
offered in a resealable, odour-proof and child-resistant pouch.
“We know our
medical clients have been waiting for this opportunity to purchase a higher
volume of cannabis without excess packaging,” said HEXO CEO and co-founder
Sebastien St-Louis. "Our Tsunami flower benefits from enhanced humidity
controls for maximum freshness and to promote ideal bud density.”
The move to a
larger format and a new type of packaging is an important step on HEXO’s
sustainability journey and provides medical clients with a more discreet option
for high volume orders.
“At
HEXO, we have a long history of medical cannabis. We offer our clients free
shipping and absorb the federal excise tax on their behalf,” added St-Louis.
“This product is being offered exclusively to medical clients and we look
forward to continuing to roll out additional strains in this format soon.”
CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and
development company, announced today a collaboration with PMI, a
subsidiary of Factoria Bogar in
Guadalajara, Mexico. PMI will have access to CURE’s innovative drug delivery
platform, CUREform™ for its drug
formulation, as well as become its distribution partner in Mexico for CURE’s
wellness products, such as its vitamin D supplement, sleep and CBD combination
products.
“This
collaboration enables us to reach new markets with our suite of wellness
products as well as prompt innovation with new drug formulations and conduct
valuable patient studies on drug efficacy,” said Rob Davidson, CEO of CURE.
“This is a valuable partnership from both a revenue perspective as well as an
opportunity to expand product offerings and research collaborations.”
PMI
will be distributing CURE’s wellness products throughout Mexico, including its
weekly vitamin D supplement and sleep aid delivered using CUREfilm® technology.
The weekly vitamin D supplements provides 50,000 IU of vitamin D3 to reduce risk of infections. CURE sleep
strips contain a soothing blend of melatonin, naturally occurring amino acids
and beneficial vitamins that promote fast-acting, balanced sleep patterns for a
deep, restful slumber and a rejuvenated awakening.
“Staying
healthy and getting enough sleep are at the top of everyone’s mind during these
very stressful days and CURE’s wellness products are welcome addition to our
offerings,” said Mauricio Villanueva, CEO of PMI and Factoria Bogar.
“Incorporating CURE’s drug delivery platform into our future drug and wellness
formulations will create new opportunities to differentiate ourselves in the
market.”
The
PMI collaboration will include several development initiatives with its
proprietary prebiotic product from Agave in combination with CBD that leverages
the CUREform™ novel delivery platform for treatment of multiple GI indications.
With CUREform, the delivery of cannabinoids is easier and more effective
because it offers increased bioavailability, simple precision of dosing and
greater palatability. There are patient studies planned for Mexico to improve
drug efficacy with CBD and prebiotics.
Once
again, today’s podcast was sponsored by Cannabis Suisse Corp. (OTC: CSUI), a research & development company licensed
under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis.
The Company's facilities for producing cannabis are based in Zurich.
The
Company grows high quality, organic cannabis with sustainable, all-natural
principles. Cannabis Suisse products are laboratory tested to ensure the end
users have access to a standardized, safe and consistent product.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com
website and this podcast is not an
ucts
or services or securities. Investors are reminded all investment involves risk
and possible loss of investment
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. Disclosure: CSUI is a paid news and social media
client
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
No comments:
Post a Comment